Abstract
Objective To investigate the clinical efficacy of DC-CIK combined with chemotherapy on patients with advanced non-small cell lung cancer and its influence on lung function. Methods A total of 100 patients with advanced non-small cell lung cancer who were admitted to hospital from February 2016 to January 2018 were selected as the subjects. According to the treatment plan, they were divided into control group and observation group, with 50 cases in each group. The control group was treated with conventional chemotherapy, and the observation group was treated with DC-CIK on the basis of the control group. Both groups were continuously treated for 3 months. After the treatment was completed, the effects were evaluated. Platinum Elite D-type pulmonary function tester was used to measure the forced expiratory volume (FEV1), forced vital capacity (FVC), and the ratio of the two (FEV1/FVC) at 1 second before treatment and 3 months after treatment; and by enzyme-linked immunosorbent assay (ELISA). The levels of interleukin-2(IL-2), interleukin-6, interleukin-10, and tumor necrosis factor-a (TNF-a) levels were measured before and after treatment in both groups; the two groups were recorded and counted after treatment. The incidences of bone marrow suppression, nausea and vomiting, leukopenia, and thrombocytopenia toxicity reactions at 3 months were compared. Results There was no significant difference in FEV1/FVC levels between the observation group and the control group at 3 months after treatment (P>0.05). The FEV1 and FVC levels in the observation group and the control group at 3 months after treatment were higher than those before treatment (P 0.05). Conclusions The application of DC-CIK combined with chemotherapy in patients with advanced non-small cell lung cancer can improve the lung function of patients, reduce the level of inflammatory factors, and does not increase the incidence of adverse reactions. It is worthy of popularization and application. Key words: DC-CIK; Chemotherapy; Advanced non-small cell lung cancer; Clinical efficacy; Pulmonary function; Inflammatory factors; Toxic side effects
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
